Lipoprotein apheresis: still needed in many patients, or soon a historical practice?

Clicks: 1
ID: 323628
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #122 of 125 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Lipoprotein apheresis (LA) has long been used as an ultima ratio therapy for patients with extreme lipid-driven cardiovascular risk. One perspective maintains that, despite major advances in lipid-lowering pharmacology and the emergence of gene-silencing therapies, LA remains indispensable for selected patients with homozygous familial hypercholesterolemia (HoFH), severe hypercholesterolemia refractory to maximal therapy, and isolated lipoprotein(a) [Lp(a)]–mediated progressive cardiovascular disease. An opposing view argues that modern and emerging pharmacological agents—PCSK9 inhibitors, inclisiran, bempedoic acid, evinacumab, and targeted Lp(a)-lowering antisense and small interfering RNA (siRNA) agents—have already rendered LA obsolete in almost all patients, with its remaining niche closing rapidly as outcome data accumulate. This combined manuscript juxtaposes the two positions in a streamlined form and concludes with a balanced conclusion of the future role of LA.
Reference Key
openalex_W7172377399 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Volker J J Schettler, Yamac Akgun, Jürgen Floege, Carmine Zoccali
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag240
URL
https://doi.org/10.1093/ckj/sfag240
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.